Coloplast A/S (COLO B.CO) Osake Kurssi
Coloplast A/S Kurssi
Liikevaihto on kasvanut 7,8 % vuodessa viimeisten 19 vuoden aikana 27,87 Mrd. DKK:een. Osakekohtainen tulos on kasvanut 11,4 % vuodessa viimeisten 19 vuoden aikana. Coloplast A/Sn nettomarginaali on nyt 13,0 %, laskenut 24,8 %:sta muutama vuosi sitten. Coloplast A/Sn osinkotuotto on tällä hetkellä noin 5,42 %. Jakosuhde on noin 142 % tuloksesta. Osinko on kasvanut 19,3 % vuodessa viimeisten 19 vuoden aikana. Analyytikoiden mediaanitavoitehinta on 642,60 DKK, eli yli nykyhintaa 51,4 %. 27 analyytikosta 9 suosittaa ostoa — kokonaiskonsensus on Pidä.
Coloplast A/S osakekurssi
Coloplast A/S liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Coloplast A/S -osakkeesta
The business model of Coloplast A/S revolves around developing and manufacturing medical devices and services that cater to the needs of individuals with intimate healthcare needs. As a leading global supplier, Coloplast focuses on urology, ostomy, continence, wound care, and skin care products. By constantly innovating and collaborating with healthcare professionals, Coloplast aims to improve the quality of life for patients worldwide. With its customer-centric approach, the company provides advanced medical solutions, education, and support to help individuals regain their independence and confidence. Coloplast A/S is committed to delivering high-quality products and services that empower individuals to live an active and fulfilling life.
Coloplast A/S is primarily active in the healthcare industry.
The main competitors of Coloplast A/S in the market include Medtronic, Hollister Incorporated, and Convatec.
Coloplast A/S is a renowned Danish medical device company specializing in developing and manufacturing products for ostomy care, urology, continence care, and wound care. Founded in 1957, Coloplast has established itself as a global leader in its field, serving patients in more than 140 countries. With a strong focus on innovation, Coloplast continuously strives to improve the quality of life for individuals with intimate healthcare needs. The company's success is attributed to its commitment to customer-centricity and its ability to anticipate and adapt to changing market demands. Over the years, Coloplast has consistently delivered innovative solutions and has built a reputation for providing exceptional products and services in the healthcare industry.
Coloplast A/S, a leading medical device company, has achieved several significant milestones throughout its history. The company has a strong track record of innovation and has consistently introduced groundbreaking products to the market. Coloplast A/S introduced the world's first disposable ostomy appliance in 1954, revolutionizing care for ostomy patients. In recent years, the company has focused on expanding its product portfolio in urology and continence care, bringing advanced solutions to patients suffering from bladder and bowel dysfunctions. With a commitment to improving the quality of life for individuals with intimate healthcare needs, Coloplast A/S continues to make strides in the medical device industry.
Coloplast A/S is primarily present in a diverse range of countries and regions worldwide. The company has a strong global presence, serving markets in Europe, North America, Latin America, Asia-Pacific, the Middle East, and Africa. With a focus on providing innovative medical solutions, Coloplast A/S has established its footprint in numerous countries, including the United States, Germany, France, China, Japan, Brazil, Australia, and South Africa. Through its widespread reach, Coloplast A/S ensures that its advanced healthcare products and services are accessible to patients and healthcare professionals across different regions, contributing to improved quality of life and better healthcare outcomes.
Coloplast A/S represents values of compassion, innovation, and responsibility in its corporate philosophy. As a global healthcare company specializing in medical products and services, Coloplast A/S is dedicated to improving the lives of individuals with intimate healthcare needs. The company emphasizes care and understanding towards its customers, striving to develop innovative solutions that enhance their quality of life. Coloplast A/S's commitment to responsible business practices is reflected in its focus on sustainability, ethics, and transparency. With its strong emphasis on compassion, innovation, and responsibility, Coloplast A/S stands as a leading healthcare company, providing essential products and services to improve the well-being of individuals worldwide.
Analyytikot asettavat tällä hetkellä Coloplast A/S-osakkeelle keskimääräisen tavoitehinnan 658,22 DKK (mediaani: 642,60 DKK), mikä merkitsee +55,1 % viimeisimpään hintaan verrattuna. Konsensus perustuu 27 analyytikkoarvioon.
27 analyytikkoa arvioi tällä hetkellä Coloplast A/S-osaketta: 9 suosittaa ostoa, 16 pitoa ja 2 myyntiä. Vuodelle 2026 analyytikot odottavat Coloplast A/S-yhtiöltä 28,85 Mrd. DKK liikevaihtoa ja 24,87 DKK osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Coloplast A/S-osake noteerataan hintaan 56,79 EUR (424,50 DKK).
Coloplast A/S-osake (COLO B.CO) on listattuna 10 pörssissä, muun muassa: London (0QBO.L), SIX (Zürich) (COLOB.SW), XETRA (CBHD.DE), Frankfurt (CBHD.F), München (CBHD.MU), Düsseldorf (CBHD.DU), Wien (COLO.VI), Kopenhagen (COLO-B.CO).
Coloplast A/S is a global company specializing in the development, manufacture, and distribution of medical devices and healthcare products. The company is divided into different business areas that focus on different customer needs. Its main business areas include continence care, wound care, and surgical products. Coloplast also offers products and services for animal continence care and wound care. The company is committed to providing high-quality products and improving patient care through innovation and collaboration with healthcare professionals. Coloplast operates in over 100 countries worldwide and strives to be a leading provider in the healthcare market.
odotettu liikevaihto Coloplast A/S on 28,85 Mrd. DKK. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Coloplast A/S on 5,60 Mrd. DKK. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Coloplast A/S:n hinta-voitto-suhde (P/E) on tällä hetkellä 17,07. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Coloplast A/S-osakkeen arvostusta.
Coloplast A/S:n hinta-myynti-suhde (P/S) on tällä hetkellä 3,31. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Coloplast A/S-osakkeen arvostuskennuslukuna.
Coloplast A/S:n Eulpool-laatuscore on 8/10.
Coloplast A/S:n ISIN on DK0060448595. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Coloplast A/S:n WKN on A1KAGC. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Coloplast A/S:n ticker on COLO B.CO. Tämä pörssinoteeraus käytetään Coloplast A/S-osakkeiden kauppaan pörssissä.
Coloplast A/S osake
Coloplast A/S vertaisryhmä
Coloplast A/S Ticker
Coloplast A/S FIGI
Kaikki tunnusluvut ja syvällinen analyysi Coloplast A/S:sta
Meidän osakeanalyysimme Coloplast A/S-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Coloplast A/S:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: